Grifols, S.A. (0RDU.IL)
- Previous Close
9.21 - Open
9.23 - Bid 9.16 x --
- Ask 9.54 x --
- Day's Range
9.11 - 9.33 - 52 Week Range
6.37 - 15.91 - Volume
259,097 - Avg. Volume
878,001 - Market Cap (intraday)
6.647B - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
58.44 - EPS (TTM)
0.16 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 3, 2021
- 1y Target Est
--
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.
www.grifols.com23,631
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 0RDU.IL
Performance Overview: 0RDU.IL
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0RDU.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0RDU.IL
Valuation Measures
Market Cap
5.64B
Enterprise Value
15.11B
Trailing P/E
103.90
Forward P/E
18.52
PEG Ratio (5yr expected)
0.33
Price/Sales (ttm)
0.96
Price/Book (mrq)
1.09
Enterprise Value/Revenue
2.29
Enterprise Value/EBITDA
12.78
Financial Highlights
Profitability and Income Statement
Profit Margin
0.13%
Return on Assets (ttm)
1.81%
Return on Equity (ttm)
1.24%
Revenue (ttm)
6.48B
Net Income Avi to Common (ttm)
8.41M
Diluted EPS (ttm)
0.16
Balance Sheet and Cash Flow
Total Cash (mrq)
541.1M
Total Debt/Equity (mrq)
121.94%
Levered Free Cash Flow (ttm)
-194.46M